Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

[1]  D. Cohen,et al.  Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections , 2021, medRxiv.

[2]  M. Nussenzweig,et al.  Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York , 2021, Nature Communications.

[3]  C. Schiffer,et al.  Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations , 2021, Immunity.

[4]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[5]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[6]  Thomas P. Fabrizio,et al.  Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants , 2021, The New England journal of medicine.

[7]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[8]  M. Diamond,et al.  SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.

[9]  C. Woods,et al.  In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.

[10]  A. Meola,et al.  Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals , 2021, bioRxiv.

[11]  C. Rice,et al.  Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.

[12]  J. Bloom,et al.  Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.

[13]  H. van Bakel,et al.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 , 2021, Cell.

[14]  James C. Crosby,et al.  Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[15]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[16]  J. Mascola,et al.  Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants , 2021, bioRxiv.

[17]  L. Ma,et al.  Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster , 2021, medRxiv.

[18]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[19]  B. Chain,et al.  Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose , 2021, Science.

[20]  Henry A. Utset,et al.  Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets , 2021, Immunity.

[21]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[22]  Aaron M. Rosenfeld,et al.  Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.

[23]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[24]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[25]  L. Walker,et al.  Prolonged evolution of the human B cell response to SARS-CoV-2 infection , 2021, Science Immunology.

[26]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.

[27]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[28]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[29]  C. Rice,et al.  Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.

[30]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[31]  A. Meola,et al.  Maturation and persistence of the anti-SARS-CoV-2 memory B cell response , 2020, Cell.

[32]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[33]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[34]  M. Nussenzweig,et al.  Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates , 2020, Cell.

[35]  Xinwen Chen,et al.  An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques , 2020, Nature Communications.

[36]  Lisa E. Gralinski,et al.  A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.

[37]  A. Mehta,et al.  Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination , 2020, Science.

[38]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[39]  C. Rice,et al.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals , 2020, Nature.

[40]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[41]  L. Gieselmann,et al.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.

[42]  C. Rice,et al.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.

[43]  L. Stamatatos,et al.  Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.

[44]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[45]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[46]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[47]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[48]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[49]  T. Kurosaki,et al.  Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting , 2019, Cell.

[50]  Peter D. Kwong,et al.  cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence , 2019, bioRxiv.

[51]  James E. Crowe,et al.  High frequency of shared clonotypes in human B cell receptor repertoires , 2019, Nature.

[52]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[53]  Steven H. Kleinstein,et al.  Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data , 2015, Bioinform..

[54]  Hao Wu,et al.  Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. , 2015, Immunity.

[55]  M. Jenkins,et al.  Apoptosis and antigen affinity limit effector cell differentiation of a single naïve B cell , 2015, Science.

[56]  Mark Mulligan,et al.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells , 2012, Proceedings of the National Academy of Sciences.

[57]  B. Pulendran,et al.  Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans , 2012, Journal of Virology.

[58]  R. Maul,et al.  Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response , 2011, Science.

[59]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[60]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[61]  R. Ahmed,et al.  Humoral immunity due to long-lived plasma cells. , 1998, Immunity.

[62]  D. Calado,et al.  Germinal Centers , 2017, Methods in Molecular Biology.

[63]  Michael T. Rosenstein,et al.  Corresponding Author’s , 1993 .